KAP Documentation: What Clinicians Must Know in 2026

For Clinicians· Reviewed by Mai Shimada, MD
Clinical documentation for ketamine therapy

The ketamine-assisted psychotherapy (KAP) market is projected to reach $3.4 billion, and with that growth comes regulatory scrutiny. DEA audits targeting controlled substance clinics have increased, and ketamine providers — particularly those offering at-home or telehealth-based treatment — face documentation requirements that go well beyond standard therapy notes.

If you are a clinician offering KAP, your documentation is your compliance. Here is what you need to know in 2026.

What Makes KAP Documentation Different

Standard psychotherapy notes follow familiar templates: presenting problem, interventions used, patient response, plan. KAP adds several layers of complexity:

Ketamine is a Schedule III controlled substance. Every prescription, every dose adjustment, and every refill must be documented with the same rigor applied to opioids or stimulants. Unlike SSRIs, you cannot simply write "continue current medication" — each prescribing decision requires clinical justification tied to documented assessment.

Dissociative state monitoring is required. During ketamine sessions, patients enter an altered state that demands real-time clinical observation. Your notes must capture vitals, level of consciousness, dissociative symptoms, and any adverse reactions at defined intervals throughout the session.

Informed consent is more detailed. Patients must understand that ketamine for depression, PTSD, and other psychiatric conditions is off-label. Your consent forms must address off-label use, potential side effects including dissociation and elevated blood pressure, the experimental nature of some treatment protocols, and alternatives to ketamine. A generic consent form will not pass regulatory review.

The KAP Documentation Checklist

Every KAP provider should maintain the following for each patient:

Pre-Treatment

  • Comprehensive screening form — psychiatric history, substance use history, cardiovascular screening, contraindication review (uncontrolled hypertension, active psychosis, pregnancy)
  • Medical history and physical exam — or documentation of coordination with the patient's PCP
  • Baseline validated measures — PHQ-9, GAD-7, PCL-5, or C-SSRS depending on the treatment indication
  • Informed consent — signed, dated, with specific language covering off-label use, risks, expected experience, and patient responsibilities

During Treatment

  • Session monitoring log — vital signs (blood pressure, heart rate, oxygen saturation) at baseline, mid-session, and pre-discharge
  • Dissociation assessment — documented at defined intervals using a standardized scale
  • Adverse event documentation — any nausea, anxiety, blood pressure elevation, or unexpected reactions, with interventions taken
  • Therapist session notes — if combining ketamine with psychotherapy, document the therapeutic content, patient responses, and integration themes separately from medical monitoring

Post-Treatment

  • Outcome tracking — validated measures at regular intervals to document treatment response
  • Prescription records — dose, formulation, quantity, date, and clinical rationale for each prescription
  • Follow-up documentation — next appointment, any dose adjustments, and clinical reasoning

DEA Compliance Requirements

As a Schedule III prescriber, you must maintain:

  • DEA registration — active and current, with the registration number linked to every prescription
  • ARCOS reporting — the Automation of Reports and Consolidated Orders System tracks Schedule II and III controlled substance transactions. Ensure your dispensing records are complete and reconcilable
  • Inventory management — if you stock ketamine on-site (for in-office sessions), you must maintain precise inventory logs with acquisition dates, quantities, and disposition records
  • Prescription monitoring — check your state's Prescription Drug Monitoring Program (PDMP) before each prescription, and document that you did so

A DEA audit will examine whether your prescribing patterns are supported by documented clinical assessments. The most common audit finding is not over-prescribing — it is inadequate documentation of the clinical rationale for prescribing.

State-Specific Telehealth Requirements

If you provide KAP via telehealth, documentation requirements vary by state. Key variables include:

  • Whether an initial in-person visit is required before telehealth prescribing
  • Whether the prescriber must be licensed in the patient's state (not just their own)
  • Telehealth-specific consent requirements
  • State-level controlled substance prescribing restrictions via telemedicine
  • Requirements for a designated "monitor" or support person to be present during at-home sessions

Document your compliance with each applicable state requirement for every patient. For a general overview of ketamine's legal status, see Is Ketamine Legal?.

Tools for KAP Documentation

Manual documentation of all these requirements is time-consuming and error-prone. Several platforms have been developed specifically for ketamine providers:

  • Mozu Health offers AI-powered documentation tools designed for KAP practices, including automated session notes, compliance tracking, and outcome measurement
  • Purpose-built EHR templates for KAP can reduce documentation time while ensuring all required elements are captured
  • Automated PDMP checks and prescription tracking reduce the risk of compliance gaps

The goal is not to spend more time on paperwork — it is to ensure that the paperwork you do produce is complete, defensible, and audit-ready.

How Isha Health Handles Compliance

At Isha Health, compliance documentation is built into every step of the treatment workflow. From initial screening through outcome tracking, our clinical team follows standardized protocols that satisfy both federal DEA requirements and state-specific telehealth regulations. This infrastructure is part of what allows us to offer safe, scalable at-home ketamine treatment.

If you are a clinician interested in how we approach compliance and clinical workflows, we welcome collaboration.


Related Articles


Are you a KAP-trained clinician? Collaborate with Isha Health or join our clinician directory.

88.8% of Isha Health patients with moderate-to-severe depression show measurable improvement

Based on 546 patients and 1,900+ validated assessments. See our clinical outcomes →

Related Posts

Trauma-informed care during ketamine therapy sessions

Trauma-Informed Care During Ketamine Treatment

Patients referred for ketamine therapy often have complex trauma histories. A 2026 clinical protocol...

TMS and ketamine combined treatment research

TMS and Ketamine Together: What Clinicians Need to Know

Can patients do TMS and ketamine concurrently? A clinical guide based on the latest research for the...

Stay informed on ketamine therapy

Research updates, clinical insights, and mental health resources — delivered to your inbox.